REMARKS

In order to expedite prosecution of this application and for no other reason, claim 21 has been canceled and reference to "prevention" and to esters, prodrugs and amides deleted from the claims.

The term "therapeutically effective in claim 14 has been replaced by reference to an amoint effective to inhibit the enzyme and antecedent basis has been provided in the definition of Ar in claim 1 to provide basis for the inclusion of compounds containing a naphthalene group in claims 6, 13 and 19.

Similarly to expedite prosecution, claim 1 has been amended to define the tricyclic heteroarlyl and substituted bicyclic heteroaryl groups more precisely, using the definitions set out for these groups in claim 2.

Having regard to the rejection under 35 USC 102, it is pointed out that Korunev describes 2-quinolyl compounds whereas the relevant compounds of present claims 1, 2, 5 - 7, 14 -16 and 19 are 3-quinolyl compounds.

So far as Nour El-Din is concerned, the benzofuran-based group of formula V

So far as Bhat is concerned, the indole-based group of its fromula III permits only methoxy or eyhoxy substituents of the benzene ring of the indole group.and so does not fall within the revised definition of Ar of at least new claim 23..

So far as Carter is concerned, the carbazole or tetrahydroarbazole groups as specified on page 2212 of the article do not fall within the definition of Ar in claim 23.

So far as Hagen is concerned, the reference to compound 8 is not understood. None of the compounds listed in column 8 of Hagan meets the definition of a substituted bicycloheteroarly group as set out in the revised claims and none is a 3-quinolinyl group.

So far as Locufiwe is concerned, compounds 111.6, 111.15 or 111.10 all bind the sulfonyl hydrazide group to a nitrogen atom of the Ar group. This is not the case of the compounds of the present invention.

Respectfully submitted,

John Richards
LADAS & PARRY LLP
26 West 61st. Street
New York, New York 10023
Reg. 31053
Tel. (212) 708-1915